Tevra's antitrust claims will fail at trial, Bayer tells US court in trial brief
MLex Summary: Bayer Healthcare argued in a trial brief that Tevra's claims that it illegally attempted to inhibit sales of generic topical imidacloprid products from 2017-20 would fail at trial. Bayer...To view the full article, register now.
Already a subscriber? Click here to view full article